NAM
VNDA icon

NorthCrest Asset Manangement’s Vanda Pharmaceuticals VNDA Stock Holding History

NorthCrest Asset Manangement’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-12,946
Closed -$82.6K – 1059
2026
Q2 		$82.6K Buy
+12,946
New +$84.6K ﹤0.01% 897

Other funds holding VNDA

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Eastern Bank
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
CFS
CGC Financial Services Lake Oswego, Oregon $451M AUM 11.72% 1-Year Est. Return

NorthCrest Asset Manangement's VNDA Position: Q3 2026 in Review

NorthCrest Asset Manangement sold out of Vanda Pharmaceuticals (VNDA) in Q3 2026, closing a stake of 12,946 shares — an estimated $82.6K sold.

NorthCrest Asset Manangement first reported a position in VNDA in Q2 2026 and held it in 1 quarter. The position peaked at $82.6K in Q2 2026. 9 funds tracked by Wall St. Rank hold VNDA as of Q3 2026.

  • NorthCrest Asset Manangement reported no remaining Vanda Pharmaceuticals position as of Q3 2026 after selling out during the quarter.
  • NorthCrest Asset Manangement sold 12,946 Vanda Pharmaceuticals shares in Q3 2026, an estimated $82.6K.
  • NorthCrest Asset Manangement first reported a position in Vanda Pharmaceuticals in Q2 2026 and held it in 1 quarter.
  • NorthCrest Asset Manangement's Vanda Pharmaceuticals position peaked at $82.6K in Q2 2026.
  • 9 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q3 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q3 2026, filed 13 Oct 2026.